Erasca, Inc.

Historical 13F Holders

Symbol
ERAS
CUSIP
29479A108
All holders as of
Q3 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 29479A108 since 12/18/2024, largest first.

Filer % of Class Filed
City Hill, LLC 13G/A
10.4% 8/14/2026
Event 6/30/2026
RTW Investments, LP 13G/A
6.4% 11/16/2026
Event 9/30/2026
Venrock Healthcare Capital Partners III, L.P. 13G/A
5.3% 5/15/2026
Event 3/31/2026
Frazier Life Sciences Public Fund, L.P. 13G/A
5.3% 8/14/2025
Event 6/30/2025
Under 5%, checked the "5 percent or less" box, or amended by a later filing (5)
T. Rowe Price Investment Management, Inc. 13G/A 4.9% 11/16/2026
Event 9/30/2026
Logos Global Management LP 13G/A
4.8% 11/14/2025
Event 9/30/2025
Novartis Pharma AG 13G/A
4.4% 2/12/2025
Event 12/31/2024
Paradigm Biocapital Advisors LP 13G/A
3.3% 5/15/2026
Event 3/31/2026
Suvretta Capital Management, LLC 13G/A
1.1% 5/12/2026
Event 3/31/2026

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 279 327 M $4.80B
2026 Q2 258 280 M $5.13B
2026 Q1 228 273 M $4.39B
2025 Q4 156 224 M $834M
2025 Q3 141 215 M $469M
2025 Q2 144 218 M $277M
2025 Q1 155 224 M $307M
2024 Q4 147 231 M $579M
2024 Q3 133 232 M $633M
2024 Q2 127 204 M $481M
2024 Q1 110 72.7 M $150M
2023 Q4 120 69.2 M $148M
2023 Q3 110 71.3 M $140M
2023 Q2 113 74.3 M $205M
2023 Q1 119 78.0 M $235M
2022 Q4 108 79.8 M $344M
2022 Q3 89 80.5 M $628M
2022 Q2 90 76.9 M $428M
2022 Q1 83 72.8 M $627M
2021 Q4 64 63.7 M $988M
2021 Q3 56 44.2 M $920M